Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera.
about
Comparison of diagnostic criteria for common variable immunodeficiency disorderEvaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccinesEfficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.Safety and immunogenicity of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian children: Booster dose and 2-dose catch-up regimens in the second year of life.Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial.Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines.A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and MaThe 7-valent pneumococcal conjugate vaccine elicits cross-functional opsonophagocytic killing responses to Streptococcus pneumoniae serotype 6D in children.Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination.Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.Anti-pneumococcal antibody titre measurement: what useful information does it yield?Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.Long-term immune responses and comparative effectiveness of one or two doses of 7-valent pneumococcal conjugate vaccine (PCV7) in HIV-positive adults in the era of combination antiretroviral therapy.Nasopharyngeal colonization: a target for pneumococcal vaccination.Poor Correlation between Pneumococcal IgG and IgM Titers and Opsonophagocytic Activity in Vaccinated Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia.Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteinsOptimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human serumReactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2-4 years: A phase II randomized study.Low opsonic activity to the infecting serotype in pediatric patients with invasive pneumococcal disease.Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children.Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity.10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix.Antibody persistence and immunologic memory in children vaccinated with 4 doses of pneumococcal conjugate vaccines: Results from 2 long-term follow-up studies.Glycoconjugate vaccines.Pneumococcal vaccine and opsonic pneumococcal antibody.New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin.10-Valent pneumococcal non-typeable haemophilus influenzae protein D-conjugate vaccine: a review in infants and children.Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concentrations determined by enzyme-linked immunosorbent assay with 22F adsorption.Vaccine profile of PPV23: Beijing Minhai Biotech 23-valent pneumococcal vaccine.Immune response to 19A serotype after immunization of 19F containing pneumococcal conjugate vaccine in Korean children aged 12-23 months.Pneumococcal conjugated vaccine: PHiD-CV.Measurement of pneumococcal polysaccharide antibodies.Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants.Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial
P2860
Q26859119-A76B854D-12F5-47B6-8207-453496C1F835Q33613509-D1D076AB-1E18-442E-909B-942C1877FB6CQ33706016-F89DD046-32C0-4333-AC90-C6CF809DA864Q33803550-F7FCD33B-C032-45FA-A65A-8E704FF87833Q34033855-F3BBE601-4E7A-4C06-9ADB-907ABC478879Q34082225-E05D6008-B191-4B89-954D-434606B5B18AQ34738780-29E31B0A-8762-400D-8DE8-6CEE38878F7CQ34867264-48C6640F-71BA-4D5B-BE34-1674F2BA4866Q35013379-85B319C1-6B9A-4F25-BAB7-62672CD77A8DQ35874108-221F2716-9D2A-4037-AB5E-01417EEAF7DEQ35887689-E2058D7F-24F9-49F5-99CB-026F88CAD74DQ36026175-B86EB941-B968-4670-9438-35125EDE48F0Q36256464-DD6DB2E5-BA78-41E7-91E7-3CAC4B273B18Q36523805-2E9B9632-A4FE-486B-A1C5-C489D10E2733Q36689018-9FA6D82C-D565-489B-A372-FA00F654F432Q36764389-A6B7813C-2A42-4092-AB1F-0B11FB12B773Q36898018-C9B468D4-C690-4DDA-B511-4EDF30285E80Q37116583-15E13CEE-27A6-4F8A-BDEC-CC3D31EDE605Q37309298-EC970E7A-BA17-49C1-8BC4-0EE533D06EFAQ37313167-96528FF7-D683-4111-8FE0-6BB3130A0FB9Q37384762-CE68010F-B0D5-4252-882E-59ECDBAE47B7Q37613613-85153EE8-B079-48FA-986B-2120536BE9CAQ37622887-66B6EBF2-F6F1-40BF-9D3F-A4C6EB76B012Q37713768-D66C9BCB-CF29-40B2-AD7A-663E258AF428Q38044755-F1740BBF-B822-471D-8337-9BC39F1C5BEBQ38105255-4C25148A-64A5-4135-B429-13DF6791C31FQ38121956-03AFBBAC-9F39-43CC-8810-9E58EDFE3E64Q38246355-DA414A17-7236-41C1-9B29-049E8D4D4F7AQ39657425-7C52B63B-0E61-4407-8E1E-9996504BE8DDQ40522492-CE8BD875-0335-461F-BB8F-AD712945EE7AQ42136104-3F5725F0-BE59-44E4-9FE3-707A8F58283CQ42638322-D57EAC61-0F9D-45CD-B428-C37D62FBBD15Q44453912-9FAB6890-FDF2-40A7-95BF-579BC6CA6F79Q54416744-50AC39C0-2292-4A0C-A333-F6825E95063FQ56337574-693D2104-74B8-41A6-8883-8E1A4B921670
P2860
Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Critical differences between p ...... centrations in pediatric sera.
@en
Critical differences between p ...... centrations in pediatric sera.
@nl
type
label
Critical differences between p ...... centrations in pediatric sera.
@en
Critical differences between p ...... centrations in pediatric sera.
@nl
prefLabel
Critical differences between p ...... centrations in pediatric sera.
@en
Critical differences between p ...... centrations in pediatric sera.
@nl
P2093
P2860
P1476
Critical differences between p ...... centrations in pediatric sera.
@en
P2093
Isabelle Henckaerts
Jan Poolman
Lindsey Ashton
P2860
P304
P356
10.1128/CVI.13.3.356-360.2006
P577
2006-03-01T00:00:00Z